Key terms
About PRTA
Prothena Corp. Plc is a clinical-stage neuroscience company, which engages in the discovery and development of novel therapies to change the course of devastating diseases. The firm’s clinical pipeline includes both wholly owned and partnered programs being developed for the potential treatment of diseases including AL amyloidosis, ATTR amyloidosis, Alzheimer’s disease, Parkinson’s disease and other neurodegenerative diseases. The company was founded in December 1969 and is headquartered in Dublin, Ireland.
Sector
Industry
Employees
Founded
Website
Key stock statistics
1-day range
52-week range
Market cap
P/E ratio
Next earnings date
Dividend yield
Ex-dividend date
Dividend pay date
Key terms
Ad Feedback
Smart score
Latest PRTA news
Apr 15
4:13pm ET
Prothena announces review on birtamimab mechanism
Mar 13
6:20am ET
Analysts Offer Insights on Healthcare Companies: Crinetics Pharmaceuticals (CRNX), Belite Bio, Inc. ADR (BLTE) and Prothena (PRTA)
Mar 07
7:36am ET
Piper Sandler Reaffirms Their Buy Rating on Prothena (PRTA)
Mar 04
4:07pm ET
Prothena names David Ford chief people officer
Feb 22
5:31pm ET
Prothena files to sell ordinary shares, no amount given
Feb 21
4:28pm ET
Prothena Appoints Daniel G. Welch as New Board Chair
Feb 21
4:26pm ET
Prothena names Daniel Welch as Director and Chair Designate
Feb 20
7:47am ET
Prothena price target lowered to $80 from $98 at Oppenheimer
Feb 18
11:45pm ET
Buy Rating Affirmed on Prothena Amid Strong Pipeline Progress and Solid Financials
Feb 16
7:40am ET
RBC Capital Reaffirms Their Hold Rating on Prothena (PRTA)
Feb 16
7:37am ET
Piper Sandler Releases a Buy Rating on Prothena (PRTA)
Feb 16
6:25am ET
Promising Outlook for Prothena’s Amyloidosis Treatments: Analyst Endorses Buy Rating
Feb 16
6:20am ET
Prothena price target raised to $85 from $81 at JMP Securities
Feb 16
1:41am ET
Wall Street Analysts Are Bullish on Top Healthcare Picks
Feb 15
4:10pm ET
Prothena reports Q4 EPS ($1.26), consensus ($1.22)
Jan 30
6:44am ET
Prothena downgraded to Neutral from Buy at BofA
Jan 25
9:30am ET
Prothena price target lowered to $36 from $43 at RBC Capital
Jan 25
7:28am ET
RBC Capital Remains a Hold on Prothena (PRTA)
Jan 17
12:15pm ET
Prothena put volume heavy and directionally bearish
No recent press releases are available for PRTA
PRTA Financials
Key terms
Ad Feedback
PRTA Forecasts
analyst rating
- buy
- hold
- sell
1-year stock price forecast
PRTA Competitors
$ Market cap
P/E ratio
$ Price
1d change
52-week range
